AGIOS PHARMACEUTICALS, INC. AGIO
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
2/9
Piotroski F — financial health
12.52
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $54.0M | -$412.8M | — | -$377.3M | $1.2B |
| 2024 | $36.5M | $673.7M | — | -$391.5M | $1.5B |
| 2023 | $26.8M | -$352.1M | — | -$297.1M | $811.0M |
| 2022 | $14.2M | -$231.8M | — | -$314.4M | $1.1B |
| 2021 | $0 | $1.6B | — | -$413.1M | $1.3B |
| 2020 | $0 | -$327.4M | — | -$304.9M | $399.5M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Ballal Rahul D. | director | 2026-06-18 | Option exercise | 2,816 | — |
| CAPELLO JEFFREY D | director | 2026-06-18 | Option exercise | 2,816 | — |
| Foster-Cheek Kaye I | director | 2026-06-18 | Option exercise | 2,816 | — |
| FOUSE JACQUALYN A | director | 2026-06-18 | Option exercise | 2,816 | — |
| Ho Maykin | director | 2026-06-18 | Option exercise | 2,816 | — |
| Owen Adams Catherine | director | 2026-06-18 | Option exercise | 2,816 | — |
| Scadden David | director | 2026-06-18 | Option exercise | 2,816 | — |
| Smith Cynthia | director | 2026-06-18 | Option exercise | 2,816 | — |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 12.52 (safe)
- Working capital / assets 0.663
- Retained earnings / assets -0.433
- EBIT / assets -0.364
- Equity / liabilities 11.46
Source: SEC EDGAR filings · CIK 0001439222 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.